Back to Feed
ClinicalTrials.gov|Clinical Trial
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Janssen Research & Development, LLC
Abstract
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd). Phase: PHASE3 Status: ACTIVE_NOT_RECRUITING Conditions: Multiple Myeloma Interventions: Cilta-cel; Pomalidomide; Bortezomib; Dexamethasone; Daratumumab
Keywords
Multiple Myeloma